Payment overview · 2025
General Payments
$1,435.79
43 reported records · 18 companies
Healthcare provider profile · identity verified
Pavan K Anand, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NAPLES, FL · NPI 1437341187
Verified facts
What the public records show
CMS Open Payments records show Pavan K Anand, M.D. received $1,435.79 in general payments during 2025 across 43 reported records.
Novartis Pharmaceuticals Corporation accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Gemtesa, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $341.47 | 23.8% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $228.05 | 15.9% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $213.68 | 14.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.12 | 9.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.83 | 8.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.51 | 4.4% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $47.72 | 3.3% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $38.15 | 2.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.14 | 2.4% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $32.26 | 2.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.22 | 1.8% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $25.48 | 1.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $24.98 | 1.7% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $22.02 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.38 | 1.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.83 | 1.3% | 1 | 2025 |
| AGEPHA Pharma FZ LLC | Unresolved — no canonical attribution shown | $18.74 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.21 | 1.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,435.79 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $341.47 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $213.68 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $124.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.93 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $103.09 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $92.79 | 4 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $63.51 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| CYGNUS DUAL Normalized: cygnus dual |
Medical Supply | Organogenesis Inc. | $38.15 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.14 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $27.07 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.22 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $25.48 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| LODOCO Normalized: lodoco |
Drug | AGEPHA Pharma FZ LLC | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.21 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 86 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 32 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 46 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1526 | 460 |
| Mounjaro | Tirzepatide | 931 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 862 | 218 |
| Pantoprazole Sodium | Pantoprazole Sodium | 545 | 202 |
| Methylprednisolone | Methylprednisolone | 505 | 329 |
| Gabapentin | Gabapentin | 410 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 373 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 347 | 108 |
| Cefuroxime | Cefuroxime Axetil | 246 | 197 |
| Eliquis | Apixaban | 242 | 71 |
| Losartan Potassium | Losartan Potassium | 230 | 71 |
| Montelukast Sodium | Montelukast Sodium | 230 | 74 |
| Omeprazole | Omeprazole | 207 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 62 |
| Celecoxib | Celecoxib | 178 | 80 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 176 | 147 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 62 |
| Lisinopril | Lisinopril | 159 | 48 |
| Spironolactone | Spironolactone | 155 | 47 |
| Carvedilol | Carvedilol | 151 | 41 |
| Metformin Hcl Er | Metformin Hcl | 149 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 142 | 52 |
| Paxlovid | Nirmatrelvir/Ritonavir | 142 | 135 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 70 |
| Repatha Sureclick | Evolocumab | 134 | 44 |
| Jardiance | Empagliflozin | 131 | 46 |
| Allopurinol | Allopurinol | 130 | 42 |
| Alprazolam | Alprazolam | 129 | 57 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 123 | 37 |
| Diclofenac Sodium | Diclofenac Sodium | 117 | 39 |
| Valsartan | Valsartan | 112 | 27 |
| Furosemide | Furosemide | 111 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 109 | 35 |
| Famotidine | Famotidine | 105 | 43 |
| Temazepam | Temazepam | 104 | 35 |
| Trulicity | Dulaglutide | 104 | 20 |
| Synthroid | Levothyroxine Sodium | 102 | 28 |
| Azithromycin | Azithromycin | 99 | 84 |
| Ipratropium Bromide | Ipratropium Bromide | 99 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 64 |
| Atenolol | Atenolol | 98 | 27 |
| Mirtazapine | Mirtazapine | 98 | 29 |
| Metformin Hcl | Metformin Hcl | 97 | 31 |
| Simvastatin | Simvastatin | 93 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 32 |
| Ezetimibe | Ezetimibe | 92 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 91 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 24 |
| Entresto | Sacubitril/Valsartan | 86 | 20 |
| Myrbetriq | Mirabegron | 84 | 26 |
| Trazodone Hcl | Trazodone Hcl | 83 | 28 |
| Xarelto | Rivaroxaban | 83 | 20 |
| Telmisartan | Telmisartan | 82 | 25 |
| Pregabalin | Pregabalin | 81 | 36 |
| Irbesartan | Irbesartan | 77 | 21 |
| Ibandronate Sodium | Ibandronate Sodium | 75 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 44 |
| Tradjenta | Linagliptin | 74 | 32 |
| Nebivolol Hcl | Nebivolol Hcl | 73 | 21 |
| Meloxicam | Meloxicam | 71 | 28 |
| Estradiol | Estradiol | 68 | 26 |
| Sertraline Hcl | Sertraline Hcl | 66 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 61 | 21 |
| Potassium Chloride | Potassium Chloride | 59 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 48 |
| Finasteride | Finasteride | 53 | 17 |
| Ozempic | Semaglutide | 53 | 12 |
| Tramadol Hcl | Tramadol Hcl | 53 | 25 |
| Repatha Syringe | Evolocumab | 52 | 11 |
| Azelastine Hcl | Azelastine Hcl | 51 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 11 |
| Valacyclovir | Valacyclovir Hcl | 50 | 27 |
| Candesartan Cilexetil | Candesartan Cilexetil | 47 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 46 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 31 |
| Donepezil Hcl | Donepezil Hcl | 40 | 14 |
| Amoxicillin | Amoxicillin | 38 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 11 |
| Clonidine Hcl | Clonidine Hcl | 38 | 11 |
| Prednisone | Prednisone | 38 | 19 |
| Ramipril | Ramipril | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 36 | 32 |
| Lubiprostone | Lubiprostone | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 27 |
| Gemtesa | Vibegron | 32 | 11 |
| Lorazepam | Lorazepam | 32 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 19 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Pindolol | Pindolol | 26 | suppressed |
| Praluent Pen | Alirocumab | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 14 |
| Levofloxacin | Levofloxacin | 25 | 22 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Torsemide | Torsemide | 24 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Silodosin | Silodosin | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 17 |
| Acyclovir | Acyclovir | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | 15 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Tadalafil | Tadalafil | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 13 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,435.79 · 43 records | Novartis Pharmaceuticals Corporation | ACCRUFER, AIRSUPRA, Arikayce, CAPVAXIVE, CRYSVITA, CYGNUS DUAL, ENTRESTO, EVENITY, GARDASIL 9, GEMTESA, JARDIANCE, KEVEYIS, Korlym, LEQVIO, LODOCO, NUZYRA, OTEZLA, REPATHA, TONMYA, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, XHANCE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error